Reconciling adherence and suspension approaches for gene therapy manufacture

Gene therapies are crucial to cure formerly untreatable diseases. With 7-log disparities in annual demand depending on indications, manufacturers may need to reach up to 1×1020 vgs capacity. This variability led to a scission between adherence and suspension-based processes, making capacity requirements and choice of expression system key in technology adoption.

To tackle this lack of flexibility novel structured fixed-bed bioreactors were developed. Integrated into intensified and continuous platforms these technologies have shown adaptability to both adherent and suspension cell culture modalities offering:

  • Increased production capacity at all scales
  • Low operational volume and commercial footprint
  • Flexibility in expression system and process parameters

To find out more about the benefits of dual platforms join us for our webinar – click here.

Subscribe to
our newsletter